2-(Hydroxymethyl)-6-methoxyoxane-3,4,5-triol | 97-30-3

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(Hydroxymethyl)-6-methoxyoxane-3,4,5-triol
• CAS: 97-30-3；3396-99-4；1824-94-8；709-50-2；617-04-9；51224-38-5；688007-20-7
• 化学式: C₇H₁₄O₆
• mdl: MFCD00066893
• 分子量: 194.18
• InChiKey: HOVAGTYPODGVJG-UHFFFAOYSA-N

物化性质

• 熔点：
  172-180 °C
• 沸点：
  250.62°C (rough estimate)
• 密度：
  1.47
• 溶解度：
  甲醇（微溶）、水（微溶）
• 物理描述：
  DryPowder
• 稳定性/保质期：
  在常温常压下稳定，白色或几乎白色的粉末。

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  29321900
• 危险品运输编号：
  NONH for all modes of transport
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存于阴凉、通风的库房。远离火种、热源，保持容器密封。应与氧化剂分开存放，切忌混储。配备相应品种和数量的消防器材。储区应备有泄漏应急处理设备和合适的收容材料。

SDS

Name:	Methyl-alpha-D-galacatopyranoside 98+% Material Safety Data Sheet
Synonym:	None Known
CAS:	3396-99-4

Section 1 - Chemical Product MSDS Name:Methyl-alpha-D-galacatopyranoside 98+% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3396-99-4	Methyl-alpha-D-galacatopyranoside	98+%	222-251-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3396-99-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 116 - 117 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble in water
Specific Gravity/Density:
Molecular Formula: C7H14O6
Molecular Weight: 194.0944

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3396-99-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl-alpha-D-galacatopyranoside - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3396-99-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3396-99-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3396-99-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性方面，甲基β-ᴅ-半乳吡喃糖（Methyl β-D-Galactopyranose, 甲基半乳糖）是一种内源性代谢物。

反应信息

• 作为反应物：
  描述：

  2-(Hydroxymethyl)-6-methoxyoxane-3,4,5-triol 生成 甲基四-O-苯甲酰基-alpha-吡喃半乳糖苷
  参考文献：
  名称：

  Tumor inhibiting saccharide conjugates

  摘要：

  本发明涉及一种制备磷酰胺糖结合物的方法，其通式为##STR1##其中糖与磷酸酰氮芥残基和伊福沙胺酰氮芥残基的连接，分别优选在1位发生，其中R.sub.1和R.sub.2；可以相同也可以不同，表示氢、较低的C.sub.1-C.sub.4烷基或C.sub.1-C.sub.6卤代烷基，而作为糖的单糖、双糖或多糖可以存在于所有已知的异构体和对映体形式中。在已知的方法中，保护溴化糖与相应的磷化合物结合，并去除保护基残基，以及将所述化合物用作抗肿瘤药物。

  公开号：

  US05622936A1

文献信息

• [EN] CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2014179620A1

  公开（公告）日：2014-11-06

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供了具有共轭基团的寡聚化合物。在某些实施例中，这些寡聚化合物与N-乙酰半乳糖结合。
• [EN] TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE<br/>[FR] NUCLÉOSIDES THÉRAPEUTIQUES CIBLÉES ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2015042447A1

  公开（公告）日：2015-03-26

  Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group comprises one or more N-Acetylgalactosamine.

  本文提供的化合物包括一个或多个治疗性核苷和一个或多个靶向基团。在某些实施例中，这些化合物进一步包括一个或多个寡核苷酸。在某些实施例中，一个靶向基团包括一个或多个N-乙酰半乳糖胺。
• ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION
  申请人：Alami Mouâd

  公开号：US20100129471A1

  公开（公告）日：2010-05-27

  The invention relates to a compound of the formula (I) in which: R 1 , R 2 and R 3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R 4 is a hydrogen atom; R 5 and R 6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

  这项发明涉及公式（I）的化合物，其中：R1、R2和R3分别是一个甲氧基基团，该基团可以选择性地被一个或多个氟原子取代；R4是一个氢原子；R5和R6相同，每个代表一个氢或氟原子；A是从包括芳基和杂环基团在内的一组环中选择的，其中这些基团可以被取代。
• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20090011994A1

  公开（公告）日：2009-01-08

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。
• NOVEL LUMINESCENT LANTHANIDE CHELATES WITH ENHANCED EXCITATION PROPERTIES
  申请人：DHR Finland OY

  公开号：US20130183771A1

  公开（公告）日：2013-07-18

  The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) wherein R 1 , R 2 and R 2* each independently are selected from carbon-containing substituents forming a C—O bond with the neighbouring oxygen atom, R 3 and R 4 each represent a bond between the chromophoric moiety and other moieties of the chelate, and Ln 3+ is a lanthanide ion, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.

  本申请公开了一种发光镧系螯合物，包括一个或多个具有以下式(I)或式(III)的色团基团，其中R1、R2和R2*各自独立地选自与相邻氧原子形成C—O键的含碳取代基，R3和R4分别代表色团基团与螯合物的其他基团之间的键，Ln3+是镧系离子，以及相应的发光镧系螯合配体。该申请还公开了一种可检测的分子，包括与发光镧系螯合物结合的生物特异性结合试剂（如抗体），以及进行生物特异性结合测定的方法，利用这种可检测的分子在利用时间分辨荧光确定特定发光的特定生物亲和性结合测定中的应用，以及与发光镧系螯合物结合的固体支持材料。